What Does Glucagon Do? A Guide to Its Application Scope
Abstract: Glucagon, a 29-amino acid peptide hormone, primarily raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. Its application scope extends beyond emergency hypoglycemia treatment to include diagnostic use in gastrointestinal imaging and potential roles in metabolic disorders. The global peptide therapeutics market, valued at over $40 billion in 2023, is driven by GLP-1 analogs and glucagon-like peptides. Key brands (e.g., Novo Nordisk’s GlucaGen, Eli Lilly’s Baqsimi) differ in delivery (injectable vs. nasal powder) and stability. Technical advantages include rapid onset; disadvantages involve short half-life and cold-chain logistics. Product parameters (purity >95%, endotoxin <1 EU/mg) and certifications (GMP, FDA/EMA approvals) are critical. Selection criteria prioritize stability, bioavailability, and manufacturer GMP compliance. Current industry trends emphasize dual-agonist peptides and lyophilized formulations for enhanced shelf life.